Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Carroll

Showing results (181-190 of 427) with videos related to

Pageof 43
Sort By:
Managed Care (Langhorne, Pa.)|October 22, 2005
Plans struggle for control of specialty pharma costsJohn Carroll
Managed Care (Langhorne, Pa.)|May 18, 2013
State laws on biosimilars may drive up plans' costsJohn Carroll
Biotechnology Healthcare|February 12, 2013
FDA proposes guidelines for access to experimental therapiesJohn Carroll
Biotechnology Healthcare|February 12, 2013
Gene therapy: science in slow motionJohn Carroll
Biotechnology Healthcare|February 21, 2013
CRO Crowing About Their GrowthJohn Carroll
Biotechnology Healthcare|February 21, 2013
Transgenics Finally Gets First Regulatory OKJohn Carroll
Biotechnology Healthcare|February 9, 2013
Will combinatorial chemistry keep its promise?John Carroll
Biotechnology Healthcare|February 9, 2013
FDA guidances on trial endpoints could change drug developmentJohn Carroll
Biotechnology Healthcare|February 2, 2013
To States unafraid of stem cell controversy, research looks like economic stuff of lifeJohn Carroll
Biotechnology Healthcare|April 6, 2012
Everyone wants in, but with no ground rules, the biosimilar business remains elusiveJohn Carroll
Pageof 43

Showing results (181-190 of 427) with videos related to

Sort By:
Pageof 43
Managed Care (Langhorne, Pa.)|October 22, 2005
Plans struggle for control of specialty pharma costsJohn Carroll
Managed Care (Langhorne, Pa.)|May 18, 2013
State laws on biosimilars may drive up plans' costsJohn Carroll
Biotechnology Healthcare|February 12, 2013
FDA proposes guidelines for access to experimental therapiesJohn Carroll
Biotechnology Healthcare|February 12, 2013
Gene therapy: science in slow motionJohn Carroll
Biotechnology Healthcare|February 21, 2013
CRO Crowing About Their GrowthJohn Carroll
Biotechnology Healthcare|February 21, 2013
Transgenics Finally Gets First Regulatory OKJohn Carroll
Biotechnology Healthcare|February 9, 2013
Will combinatorial chemistry keep its promise?John Carroll
Biotechnology Healthcare|February 9, 2013
FDA guidances on trial endpoints could change drug developmentJohn Carroll
Biotechnology Healthcare|February 2, 2013
To States unafraid of stem cell controversy, research looks like economic stuff of lifeJohn Carroll
Biotechnology Healthcare|April 6, 2012
Everyone wants in, but with no ground rules, the biosimilar business remains elusiveJohn Carroll
Pageof 43